NICE releases guidance on cabazitaxel for prostate cancer

NICE (National Institute for Health and Clinical Excellence) has released guidance concerning the effect of cabazitaxel for hormone-refactory metastatic prostate cancer. Of particular note is NICE'S recommendation that cabazitaxel should not be used in combination with prednisone or prednisolene to treat this form of cancer, particularly after docetaxel treatment. Further information on this recommendation, including access to both the full guidance and patient version can be found here